Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendment to its restated certificate with the Secretary of State of the State of Delaware that will effect the previously announced one-for-15 reverse stock split of its common stock.  The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. On November 15, 2019, Alimera’s common stock will begin trading on a post-reverse stock split basis on The Nasdaq Global Market under the existing symbol “ALIM.”
About Alimera Sciences, Inc.Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit Statements

This press release contains a “forward-looking statement” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Alimera’s expectation that its common stock will trade The Nasdaq Global Market on a post-reverse stock split basis on November 15, 2019. The forward-looking statement is based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change this expectation, and could cause actual results to differ materially from those projected in the forward-looking statement. Meaningful factors that could cause actual results to differ include, but are not limited to, unforeseen technical issues that could result in Alimera’s common stock not trading on The Nasdaq Global Stock Market on a post-reverse stock split basis on November 15, 2019 as expected.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.